• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 2Reboxetine – evidence map for acute trials

RBX vs. plcRBX vs. SSRIaRBX vs. FLURBX vs. PARRBX vs. CITRBX vs. CIT long-termRBX vs. TCARBX vs. IMIRBX vs. DOT
Outcome
RemissionR−
ResponseH: (R+)R−R−no statementb
O: ↔
Depression scale total scoreH: ↔no statementbno datano statementb
O: ↔
Social functioning levelno data
Health-related quality of life
Mortality(↔)(↔)(↔)(↔)no data(↔)(↔)(↔)(↔)
Suicidal tendencies(↔)(↔)(↔)(↔)no data(↔)(↔)(↔)(↔)
Suicide attempts & suicides(↔)(↔)(↔)(↔)no data(↔)(↔)(↔)(↔)
SAEno datano statementb
AER−all: ↔no data(R−)
M: R−W: ↔
Discontinuations due to AER−no statementbR−no data(R−)no statementb(R−)

R+/R−: proof of superiority/inferiority of reboxetine

(R+)/(R−): indication of superiority/inferiority of reboxetine

↔ : no proof of superiority or inferiority of one of the 2 treatment options

(↔): no proof of superiority or inferiority of one of the 2 treatment options, with insufficient data

Empty cells: no data available

a

Findings from the only long-term acute trial not included

b

Due to heterogeneity, no statement on benefit compared to the drug class

AE: adverse events; CIT: citalopram; DOT: dothiepin; FLU: fluoxetine; H: hospitalized patients; IMI: imipramine; M: men; O: outpatients; PAR: paroxetine; plc: placebo; SAE: serious adverse events; SSRI: selective serotonin reuptake inhibitors; TCA: tricyclic antidepressants; vs.: versus; W: women

Findings from the only long-term acute trial not included

Due to heterogeneity, no statement on benefit compared to the drug class

© IQWiG (Institute for Quality and Efficiency in Health Care)

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.